HomeCompareCHJTF vs KMB

CHJTF vs KMB: Dividend Comparison 2026

CHJTF yields 3.02% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHJTF wins by $44.85M in total portfolio value· pulled ahead in Year 2
10 years
CHJTF
CHJTF
● Live price
3.02%
Share price
$1.02
Annual div
$0.03
5Y div CAGR
87.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.89M
Annual income
$39,983,177.94
Full CHJTF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — CHJTF vs KMB

📍 CHJTF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHJTFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHJTF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHJTF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHJTF
Annual income on $10K today (after 15% tax)
$256.35/yr
After 10yr DRIP, annual income (after tax)
$33,985,701.25/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, CHJTF beats the other by $33,981,262.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHJTF + KMB for your $10,000?

CHJTF: 50%KMB: 50%
100% KMB50/50100% CHJTF
Portfolio after 10yr
$22.47M
Annual income
$19,994,200.14/yr
Blended yield
88.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

CHJTF
No analyst data
Altman Z
5.9
Piotroski
5/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHJTF buys
0
KMB buys
0
No recent congressional trades found for CHJTF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHJTFKMB
Forward yield3.02%5.25%
Annual dividend / share$0.03$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR87.3%17%
Portfolio after 10y$44.89M$45.9K
Annual income after 10y$39,983,177.94$5,222.34
Total dividends collected$44.48M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CHJTF vs KMB ($10,000, DRIP)

YearCHJTF PortfolioCHJTF Income/yrKMB PortfolioKMB Income/yrGap
1$11,265$564.87$11,314$614.45$49.00KMB
2← crossover$13,167$1,113.86$12,867$760.19+$300.00CHJTF
3$16,368$2,279.06$14,713$945.27+$1.7KCHJTF
4$22,473$4,959.20$16,924$1,181.90+$5.5KCHJTF
5$35,965$11,918.72$19,596$1,486.64+$16.4KCHJTF
6$71,871$33,388.76$22,850$1,882.16+$49.0KCHJTF
7$193,699$116,796.73$26,849$2,399.80+$166.8KCHJTF
8$758,265$551,007.12$31,812$3,083.36+$726.5KCHJTF
9$4,587,110$3,775,766.40$38,033$3,994.72+$4.55MCHJTF
10$44,891,385$39,983,177.94$45,918$5,222.34+$44.85MCHJTF

CHJTF vs KMB: Complete Analysis 2026

CHJTFStock

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Full CHJTF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this CHJTF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHJTF vs SCHDCHJTF vs JEPICHJTF vs OCHJTF vs KOCHJTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.